SCHEMBL29816629

SCHEMBL29816629

c1ccc(COc2ccccn2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.61
CYP2C19 P33261 2/20 0.61
NPC1 O15118 1/20 0.61
CYP2D6 P10635 1/20 0.61
LTA4H P09960 1/20 0.52
MAPK14 Q16539 1/20 0.52
GABRA5 P31644 2/20 0.47
TSHR P16473 2/20 0.46
PKM P14618 1/20 0.46
CYP3A4 P08684 1/20 0.46
LMNA P02545 2/20 0.45
CYP1A2 P05177 1/20 0.45
PTGS1 P23219 1/20 0.45
SLC6A2 P23975 1/20 0.45
PTGS2 P35354 1/20 0.45
SLC6A3 Q01959 1/20 0.45
HIF1A Q16665 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
MAPT P10636 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL223680 1.00 ALDH1A1 (0.61) ALDH1A1CYP2C19NPC1CYP2D6LTA4H
Formaldehyde SCHEMBL29285221 0.94 CYP2C19 (0.56) ALDH1A1CYP2C19NPC1CYP2D6LTA4H
SCHEMBL10055039 0.93 NPC1 (0.68) ALDH1A1CYP2C19NPC1CYP2D6LTA4H
SCHEMBL6130101 0.88 NPC1 (0.58) ALDH1A1CYP2C19NPC1CYP2D6LTA4H
SCHEMBL510167 0.84 NPC1 (0.58) ALDH1A1CYP2C19NPC1CYP2D6LTA4H
SCHEMBL510090 0.84 NPC1 (0.63) ALDH1A1CYP2C19NPC1CYP2D6LTA4H
SCHEMBL510400 0.84 NPC1 (0.58) ALDH1A1CYP2C19NPC1CYP2D6LMNA
SCHEMBL21054861 0.84 NPC1 (0.58) ALDH1A1CYP2C19NPC1CYP2D6LTA4H
SCHEMBL18429765 0.84 NPC1 (0.58) ALDH1A1CYP2C19NPC1CYP2D6CYP3A4
SCHEMBL31473741 0.84 NPC1 (0.58) ALDH1A1CYP2C19NPC1CYP2D6LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3500572-B1 CYTISINE DERIVATIVES FOR THE TREATMENT OF ADDICTION UNIV BRISTOL (GB) 2022-10-26 EP claimed
US-20240254093-A1 GPR35 Agonist Compounds NXERA PHARMA UK LIMITED (GB) 2024-08-01 US disclosed
US-20240180886-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE BRISTOL-MYERS SQUIBB COMPANY (US) 2024-06-06 US disclosed
US-20240182490-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2024-06-06 US disclosed
US-11753376-B2 Benzyloxy pyridine derivatives and uses thereof AUTOTAC INC. (KR) 2023-09-12 US disclosed
US-20220315601-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2022-10-06 US disclosed
US-20220298113-A1 BENZYLOXY PYRIDINE DERIVATIVES AND USES THEREOF AUTOTAC INC. (KR) 2022-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240254093-A1 GPR35 Agonist Compounds GPR35, GPR119, GPR68 ALDH1A1 1962/4885CYP2C19 2608/4885NPC1 493/4885
US-20240182490-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 ALDH1A1 3316/4885CYP2C19 4857/4885NPC1 2992/4885
US-11753376-B2 Benzyloxy pyridine derivatives and uses thereof SQSTM1, ATG7, BECN1 ALDH1A1 3915/4885CYP2C19 3729/4885NPC1 601/4885
US-20220315601-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 ALDH1A1 3316/4885CYP2C19 4857/4885NPC1 2992/4885
US-20240180886-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE PTPN2, PTPN22, PTPN1 ALDH1A1 3561/4885CYP2C19 1459/4885NPC1 2974/4885
US-20220298113-A1 BENZYLOXY PYRIDINE DERIVATIVES AND USES THEREOF SQSTM1, ATG7, BECN1 ALDH1A1 3915/4885CYP2C19 3729/4885NPC1 601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.